Article
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
JAMA network open - 5 Feb 2020
Catenacci Daniel V T, Chase Leah, Lomnicki Samantha, Karrison Theodore, de Wilton Marsh Robert, Rampurwala Murtuza M, Narula Sunil, Alpert Lindsay, Setia Namrata, Xiao Shu-Yuan, Hart John, Siddiqui Uzma D, Peterson Bryan, Moore Kelly, Kipping-Johnson Kristin, Markevicius Ugne, Gordon Barbara, Allen Kenisha, Racette Christine, Maron Steven B, Liao Chih-Yi, Polite Blase N, Kindler Hedy L, Turaga Kiran, Prachand Vivek N, Roggin Kevin K, Ferguson Mark K, Posner Mitchell C
Abstract excerpt
Importance: Patients with locally advanced gastroesophageal adenocarcinoma (ie, stage ≥T3 and/or node positive) have high rates of recurrence despite surgery and adjunctive perioperative therapies, which also have high toxicity profiles. Evaluation of pharmacogenomically dosed perioperative gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) to optimize efficacy while...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.